

Freda H Passam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9376078/publications.pdf>

Version: 2024-02-01

55
papers

2,991
citations

159525

30
h-index

182361

51
g-index

57
all docs

57
docs citations

57
times ranked

3828
citing authors

#	ARTICLE	IF	CITATIONS
1	Îeta-2-glycoprotein I exerts antithrombotic function through its domain V in mice. <i>Journal of Autoimmunity</i> , 2022, 126, 102747.	3.0	3
2	Mechano-Redox Control of Integrins in Thromboinflammation. <i>Antioxidants and Redox Signaling</i> , 2022, 37, 1072-1093.	2.5	1
3	An alternate covalent form of platelet Î±IIbÎ²3 integrin that resides in focal adhesions and has altered function. <i>Blood</i> , 2021, 138, 1359-1372.	0.6	8
4	Thromboinflammation Model-on-A-Chip by Whole Blood Microfluidics on Fixed Human Endothelium. <i>Diagnostics</i> , 2021, 11, 203.	1.3	8
5	Protein Disulphide Isomerase 6 (PDIA6) Attenuates Platelet Endoplasmic Reticulum Stress and Secretion in a Mouse Model. <i>Blood</i> , 2021, 138, 3138-3138.	0.6	0
6	Functional Assays of Thiol Isomerase ERp5. <i>Methods in Molecular Biology</i> , 2019, 1967, 149-163.	0.4	3
7	Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. <i>Nature Communications</i> , 2019, 10, 1322.	5.8	277
8	Straight Channel Microfluidic Chips for the Study of Platelet Adhesion under Flow. <i>Bio-protocol</i> , 2019, 9, e3195.	0.2	7
9	Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 392-399.	0.7	52
10	Autoregulation of von Willebrand factor function by a disulfide bond switch. <i>Science Advances</i> , 2018, 4, eaaq1477.	4.7	79
11	Investigation of redox modifications of platelet integrin GPIIb-IIIa in diabetes. <i>Free Radical Biology and Medicine</i> , 2018, 128, S55.	1.3	0
12	Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2322-2335.	1.9	29
13	Mechano-redox control of integrin de-adhesion. <i>ELife</i> , 2018, 7, .	2.8	47
14	Neutrophil Activation and Netosis Are the Key Drivers of Thrombosis in Heparin-Induced Thrombocytopenia. <i>Blood</i> , 2018, 132, 378-378.	0.6	3
15	Îeta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner. <i>Scientific Reports</i> , 2017, 7, 8201.	1.6	9
16	Protein Disulfide Isomerase in Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 765-773.	1.5	20
17	Both platelet- and endothelial cell-derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis. <i>Blood</i> , 2015, 125, 2276-2285.	0.6	59
18	Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its Î²x Domain. <i>Journal of Biological Chemistry</i> , 2015, 290, 23543-23552.	1.6	90

#	ARTICLE	IF	CITATIONS
19	Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. Journal of Clinical Investigation, 2012, 122, 2104-2113.	3.9	257
20	Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. Journal of Clinical Investigation, 2012, 122, 558-568.	3.9	150
21	The interaction of Beta 2 Glycoprotein I with vWF is thiol dependent and promotes the binding of GPIIb/IIIa to vWF: Implications to the redox regulation of platelet adhesion. Clinical Biochemistry, 2011, 44, S255.	0.8	0
22	Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. Journal of Thrombosis and Haemostasis, 2011, 9, 275-282.	1.9	56
23	Protein Disulfide Isomerase Inhibitors: A New Class of Antithrombotic Agents. Blood, 2011, 118, 369-369.	0.6	2
24	Role of Thiol Isomerase ERp5 in Thrombus Formation. Blood, 2011, 118, 370-370.	0.6	1
25	Naturally occurring free thiols within Î2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood, 2010, 116, 1961-1970.	0.6	105
26	Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood, 2010, 116, 1995-1997.	0.6	60
27	Redox control of Î2-glycoprotein I-von Willebrand factor interaction by thioredoxin1. Journal of Thrombosis and Haemostasis, 2010, 8, 1754-1762.	1.9	52
28	In vivo modulation of angiogenesis by beta 2 glycoprotein I. Journal of Autoimmunity, 2010, 35, 232-240.	3.0	23
29	Histological expression of angiogenic factors: VEGF, PDGFRÎ±, and HIF-1Î± in Hodgkin lymphoma. Pathology Research and Practice, 2009, 205, 11-20.	1.0	36
30	How we diagnose the antiphospholipid syndrome. Blood, 2009, 113, 985-994.	0.6	167
31	Î2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. Journal of Thrombosis and Haemostasis, 2008, 6, 1215-1223.	1.9	44
32	Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood, 2007, 109, 422-430.	0.6	208
33	Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. International Journal of Laboratory Hematology, 2007, 30, 070129105256005-???	0.2	10
34	Thymoma with immunodeficiency (Good's syndrome): Review of the literature apropos three cases. Scandinavian Journal of Infectious Diseases, 2006, 38, 314-320.	1.5	28
35	Angiogenic Molecules in Hodgkin's Disease: Results from Sequential Serum Analysis. International Journal of Immunopathology and Pharmacology, 2006, 19, 205873920601900.	1.0	19
36	Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: a methodological approach. Annals of Hematology, 2006, 85, 795-805.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2005, 29, 41-46.	0.4	36
38	Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2005, 42, 393-399.	1.8	38
39	Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. <i>Journal of Autoimmunity</i> , 2005, 25, 283-288.	3.0	29
40	Laboratory tests for the antiphospholipid syndrome: current concepts. <i>Pathology</i> , 2004, 36, 129-138.	0.3	30
41	Pleural Effusions in Hematologic Malignancies. <i>Chest</i> , 2004, 125, 1546-1555.	0.4	194
42	Intestinal ischemia as the first manifestation of vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 431-441.	1.6	43
43	Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. <i>Journal of Molecular Histology</i> , 2004, 35, 857-863.	1.0	14
44	Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. <i>American Journal of Hematology</i> , 2004, 75, 101-106.	2.0	37
45	Clinical significance of circulating endothelial adhesion molecules (sE-selectin and sICAM) in untreated multiple myeloma patients. <i>Clinica Chimica Acta</i> , 2004, 349, 39-43.	0.5	11
46	Ki-67 Proliferation Index. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 8-13.	0.6	57
47	Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. <i>Annals of Hematology</i> , 2003, 82, 19-23.	0.8	57
48	Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity. <i>American Journal of Hematology</i> , 2003, 72, 229-233.	2.0	49
49	Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 679-685.	1.8	27
50	Levels of Serum Cytokines and Acute Phase Proteins in Patients With Essential and Cancer-Related Thrombocytosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 135-140.	0.6	142
51	Levels of Serum Cytokines and Acute Phase Proteins in Patients With Essential and Cancer-Related Thrombocytosis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 135-140.	0.6	126
52	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1383-1387.	0.8	33
53	Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. <i>Clinica Chimica Acta</i> , 2002, 325, 51-57.	0.5	38
54	Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. <i>Annals of Hematology</i> , 2001, 80, 349-353.	0.8	38

#	ARTICLE	IF	CITATIONS
55	Activated peripheral blood and endothelial cells in thalassemia patients. <i>Annals of Hematology</i> , 2001, 80, 577-583.	0.8	71